Announcement of Availability to Investigators of Amivantamab

September 01, 2023

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using amivantamab, an epidermal growth factor receptor (EGFR)- and MET proto-oncogene (MET)- targeting bispecific antibody, which is being developed by CTEP as an anticancer agent in collaboration with Janssen Pharmaceuticals. CTEP will also consider requests to supply amivantamab for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

If you are a DFHCC Investigator interested in submitting an LOI using Amivantamab through the ETCTN, please contact Dr. Geoffrey Shapiro (

Questions may be addressed to Dr. Cheryl Pickett ( Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (

For more information please see the related documents below